On August 26, according to BIT (bit.com) market data, biopharmaceutical stocks are experiencing speculation, with US-based Moderna (MRNA) closing up 14.36% and a trading volume reaching $7.636 billion. Merck (MRK) also saw an increase of 3.84%. Recently, Moderna and Merck jointly announced the successful results of their first personalized mRNA cancer therapy, intismeran autogene, in a global Phase III clinical trial targeting high-risk melanoma, marking a milestone breakthrough in the field of tumor immunotherapy. Several major banks have raised their price targets for Moderna; Bank of America increased its target from $40 to $170, upgrading its rating to 'Neutral'; Piper Sandler raised its target from $77 to $167, maintaining an 'Overweight' rating; Goldman Sachs raised its target from $67 to $120, keeping a 'Neutral' rating; and JPMorgan increased its target from $40 to $77, while Barclays raised its target from $48 to $125. According to Bitget market data, after the opening of the Hong Kong stock market today, CanSino Biologics surged over 17%, Innovent Biologics rose over 10%, Genting Yongying increased over 7%, Kintor Pharmaceutical rose over 6%, and Rongchang Biologics was up over 4%. CanSino Biologics announced that its subsidiary, CanSino Shanghai, has officially signed a strategic cooperation framework agreement with Depu Bio to jointly advance the research and commercialization of mRNA personalized therapeutic cancer vaccines.